Vycor Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite


Vycor Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite

PR Newswire

BOCA RATON, Fla., June 25, 2015 /PRNewswire/ — Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the commercial release of its Internet-delivered therapy suite in the U.S. This therapy suite, consisting of its lead Vision Restoration Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is delivered directly to patients over the Internet onto their own computers replacing the Company’s current “prototype hardware centric” model.

NovaVision has been working to take its VRT therapy prototype and develop it into an affordable, scalable therapy offering that offers broader patient benefits. VRT will going forward be provided alongside NovaVision’s NeuroEyeCoach compensatory therapy in one Internet delivered therapy suite. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients’ difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision, The two therapies provided in a suite are therefore highly complementary and ensure broad benefits to NovaVision’s patients.

NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on its strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering visual impairment following neurological damage; and to offer solutions for both patients and physicians alike.

For Patients:

  • VRT and NeuroEyeCoach Therapy Suite. NovaVision will commercially launch this week these two complementary therapies, internet-delivered in a package for $900.
  • NeuroEyeCoach. For patients with visual impairments who are not suitable, for whatever reason, for VRT, NovaVision provides NeuroEyeCoach on its own for $450.
For Physicians:
  • Vision Diagnostic (VIDIT). The diagnostic component of VRT that enables therapists to perform high-resolution visual field tests in less than 10 minutes to screen for visual field deficits.
  • NeuroEyeCoach Pro Center. Enables stroke rehabilitation and other centers to treat patients while in their care, both as in-patient and out-patient.
  • NovaVision and NeuroEyeCoach Pro Physician. Enables physicians to register patients in their clinic who complete the therapy at home, supported by NovaVision but monitored by the physician through a dedicated portal.

VRT is a prescription product and the only FDA cleared therapy (510k) for the restoration of vision loss from neurological damage. VRT is supported by 15 years of clinical research and over 20 studies including a 302 patient study in which notable improvements were seen in 70% of the patients. NeuroEyeCoach is also clinically supported being based on research that has been the subject of 14 clinical studies on a total of 591 patients and has FDA registration.

Commenting on the Company’s announcement, Peter Zachariou, CEO of Vycor, stated: “This has been a long time coming and has entailed an enormous amount of work from both our employees but also our scientific advisors and is a key milestone for NovaVision. We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution. I am convinced that this new therapy suite is the most robust, affordable and complete commercially available visual therapy solution targeted at this type of vision loss. This also represents the final step in moving NovaVision from being a development company to one focused on commercializing its unique suite of products. I would urge anyone who has had a stroke or brain injury and suffers from a visual disorder to contact us, we have numerous testimonials of patients for whom these therapies have literally changed their lives”.

There are approximately 8m stroke survivors in the U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of Traumatic Brain Injury (TBI) annually; up to 30% of these suffer a resultant visual impairment, up to 20% permanently. In all, around 2.8 million Americans suffer from this type of vision impairment, which is largely unaddressed by the rehabilitation system. The impact on their daily lives is dramatic, and is the difference between a person being able to be home alone, cross the road unaided, drive, shop or read. The new therapy suite is targeted at this largely underserved group of people.

For an overview of NovaVision see NovaVision Video.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s